# Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme

> **NCT02017249** · PHASE1 · COMPLETED · sponsor: **Inova Health Care Services** · enrollment: 1 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** arginine in powder form
- **DRUG:** Silica and cellulose placebo powder

## Key facts

- **NCT ID:** NCT02017249
- **Lead sponsor:** Inova Health Care Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-09
- **Final completion:** 2015-10-06
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2019-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02017249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02017249, "Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02017249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*